3 results
Approved WMOCompleted
Primary: To evaluate the efficacy of repeated subcutaneous (SC) administrations of lanadelumab in preventing angioedema attacks in adolescents (12 to <18 years of age) and adults with non-histaminergic angioedema with normal C1-INH.Secondary…
Approved WMOCompleted
The objectives of this study:• To generate the proof of concept for lanadelumab for treatment of symptoms of COVID-19 disease • To demonstrate its safety after intravenous administration.
Approved WMORecruiting
Assessment of safety and clinical performance of the DREAMS 3G in de novo coronary artery lesion in order to achieve and to obtain CE-approval